TORONTO--(BUSINESS WIRE)--Biovail Corporation today announced that Xenazine® tablets, an orphan drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington’s disease (HD), is now available throughout the United States. Xenazine® is the first and only FDA-approved treatment for any HD-related symptom.
